- Home
- EBS vs NMAI Comparison
EBS vs NMAI Comparison
Compare EBS & NMAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBS
- NMAI
- Stock Information
- Founded
- EBS 1998
- NMAI 2021
- Country
- EBS United States
- NMAI United States
- Employees
- EBS N/A
- NMAI N/A
- Industry
- EBS Biotechnology: Pharmaceutical Preparations
- NMAI Investment Managers
- Sector
- EBS Health Care
- NMAI Finance
- Exchange
- EBS Nasdaq
- NMAI Nasdaq
- Market Cap
- EBS 423.6M
- NMAI 429.9M
- IPO Year
- EBS 2006
- NMAI N/A
- Fundamental
- Price
- EBS $9.11
- NMAI $13.03
- Analyst Decision
- EBS Strong Buy
- NMAI
- Analyst Count
- EBS 2
- NMAI 0
- Target Price
- EBS $13.50
- NMAI N/A
- AVG Volume (30 Days)
- EBS 969.4K
- NMAI 74.8K
- Earning Date
- EBS 10-29-2025
- NMAI 01-01-0001
- Dividend Yield
- EBS N/A
- NMAI 13.14%
- EPS Growth
- EBS N/A
- NMAI N/A
- EPS
- EBS 2.53
- NMAI 0.64
- Revenue
- EBS $851,600,000.00
- NMAI N/A
- Revenue This Year
- EBS N/A
- NMAI N/A
- Revenue Next Year
- EBS $19.24
- NMAI N/A
- P/E Ratio
- EBS $3.63
- NMAI $19.03
- Revenue Growth
- EBS N/A
- NMAI N/A
- 52 Week Low
- EBS $4.02
- NMAI $10.60
- 52 Week High
- EBS $12.73
- NMAI $12.55
- Technical
- Relative Strength Index (RSI)
- EBS 54.66
- NMAI 54.26
- Support Level
- EBS $9.07
- NMAI $12.75
- Resistance Level
- EBS $10.10
- NMAI $13.25
- Average True Range (ATR)
- EBS 0.49
- NMAI 0.14
- MACD
- EBS 0.01
- NMAI -0.01
- Stochastic Oscillator
- EBS 53.00
- NMAI 52.00
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
About NMAI Nuveen Multi-Asset Income Fund of Beneficial Interest
Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund may invest in equity and debt securities of any type without limit.